NASDAQ:NVLN - Novelion Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.41 -0.22 (-6.06 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$3.41
Today's Range$3.38 - $3.69
52-Week Range$3.08 - $10.68
Volume1.63 million shs
Average Volume44,576 shs
Market Capitalization$67.90 million
P/E Ratio-0.50
Dividend YieldN/A
Beta0.85
Novelion Therapeutics logoNovelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVLN
CUSIPN/A
Phone617-500-7867

Debt

Debt-to-Equity Ratio-21.68
Current Ratio1.65
Quick Ratio1.42

Price-To-Earnings

Trailing P/E Ratio-0.50
Forward P/E Ratio-0.56
P/E GrowthN/A

Sales & Book Value

Annual Sales$138.44 million
Price / Sales0.46
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book4.26

Profitability

EPS (Most Recent Fiscal Year)($6.81)
Net Income$-126,710,000.00
Net Margins-94.58%
Return on Equity-240.54%
Return on Assets-19.41%

Miscellaneous

Employees180
Outstanding Shares18,700,000

The Truth About Cryptocurrencies

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($1.76) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $1.42. The biotechnology company earned $27.48 million during the quarter. Novelion Therapeutics had a negative return on equity of 240.54% and a negative net margin of 94.58%. View Novelion Therapeutics' Earnings History.

When is Novelion Therapeutics' next earnings date?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Novelion Therapeutics.

What price target have analysts set for NVLN?

1 analysts have issued 12 month target prices for Novelion Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Novelion Therapeutics' share price to reach $6.00 in the next year. View Analyst Ratings for Novelion Therapeutics.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:
  • Mr. Michael D. Price, Sr. VP & CFO (Age 60)
  • Mr. Jeffrey S. Hackman, Exec. VP & COO (Age 56)
  • Dr. Murray Stewart M.D., Exec. VP and Head of R&D (Age 58)
  • Mr. Benjamin S. Harshbarger, Gen. Counsel (Age 49)
  • Mr. Roger W. Louis, Global Chief Compliance Officer & Sr. VP (Age 62)

Has Novelion Therapeutics been receiving favorable news coverage?

Headlines about NVLN stock have been trending somewhat negative recently, according to Accern Sentiment. The research firm rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novelion Therapeutics earned a daily sentiment score of -0.02 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 44.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Novelion Therapeutics' major shareholders?

Novelion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Prosight Management LP (1.25%), Schwab Charles Investment Management Inc. (0.52%), Dimensional Fund Advisors LP (0.30%) and Millennium Management LLC (0.19%). Company insiders that own Novelion Therapeutics stock include Donald K Stern, Jason Aryeh and Stonepine Capital, LP. View Institutional Ownership Trends for Novelion Therapeutics.

Which major investors are selling Novelion Therapeutics stock?

NVLN stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Prosight Management LP, Schwab Charles Investment Management Inc. and Millennium Management LLC. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $3.41.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $67.90 million and generates $138.44 million in revenue each year. The biotechnology company earns $-126,710,000.00 in net income (profit) each year or ($6.81) on an earnings per share basis. Novelion Therapeutics employs 180 workers across the globe.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NVLN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.